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Figure 1. Comparison of Intraindividual % Change of Normalized PAV and
TAV Between the Segments With Endothelial Dysfunction and Those
With Normal Endothelial Function
The % change of normalized percent atheroma volume (PAV) is shown in the
upper left panel and of total atheroma volume (TAV) in the upper right
panel. The comparison is between segments with endothelial dysfunction and
those with normal endothelial function. Representative examples of intravas-
cular ultrasound (IVUS) ﬁndings are shown in the lower panel. Segments with
endothelial dysfunction showed greater progression in PAV (*p < 0.05) and
TAV (p ¼ 0.065) than segments with normal endothelial function from the
same subject. IVUS demonstrates the progression of disease-only segments
with endothelial dysfunction (lumen traced in green, external elastic mem-
brane in yellow).
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10470% plaque burden and IVUS-VH–derived thin-capped ﬁbroa-
theroma are more likely associated with the progression of athero-
sclerosis and recurrent coronary events (4). Thus, the current study
extends these previous observations and demonstrates that coronary
artery segments with relatively small plaque burden, but evidence of
endothelial dysfunction, show faster plaque progression over a rela-
tively short period of time than segmentswith similar plaque burden at
baseline, but normal endothelial function. Thus, segments with
endothelial dysfunction may represent the earliest identiﬁable site
with underlying vascular injury, but abnormal repair prone to accel-
erated plaque progression and complications.
The mechanism for plaque progression at the segments with
endothelial dysfunction may be multifactorial, but the reduced activity
of endothelium-dependent vasodilators, particularly nitric oxideactivity, an increased activity of vasoconstrictors with mitogenic ac-
tivity, and altered anti-inﬂammatory and anticoagulant properties of
the endothelium likely contribute to accelerated plaque progression.
The lack of correlation between the severity of endothelial
dysfunction and plaque progression suggests that plaque progression
is independent of changes in the degree of coronary endothelial
reactivity.
In conclusion, atherosclerosis is a diffuse and systemic disease
with focal complications. The ability of in vivo identiﬁcation of
coronary artery segments with propensity for plaque vulnerability
that are at risk for plaque progression and the development of car-
diovascular events may potentially have implications for future site-
speciﬁc therapy beyond the systemic therapy for patients in early
coronary atherosclerosis.
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Deﬁnitions of Outcome, Response
and Effect in Imaging Research to
Avoid Confusion
“Outcome,” “response,” and “effect” are not the same. Unfortunately,
these terms are commonly used interchangeably in imaging research,
which can lead to problems with study design and misinterpretation
of results. We propose and illustrate simple deﬁnitions to allow these
fundamentally different concepts to be distinguished for clear
communication between authors and readers of scientiﬁc papers.
OUTCOME
“Outcome” is a measured value, which can be a state of health or an
event, subsequent to an intervention. Outcome data is easy to
Figure 1. Why “Outcome,” “Response,” and “Effect” are Distinct
“Outcome” is a measured value subsequent to an intervention. “Response” is the change in a measured variable from before to after an intervention. “Effect” is the
difference in response between an intervention group and a control group.
Figure 2. An Example That Illustrates How Commonly These Terms are
Used to Describe the Same Concept
We examined 61 studies of cardiac resynchronization therapy (CRT). There was
inconsistency in the use of the terms “outcome,” “response,” and “effect.”
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105obtain, as it requires only 1 measurement and no knowledge of
measurements made prior to intervention. It can be a useful and
valid method for assessing whether health care needs have been met
or not.
RESPONSE
“Response” is the change in a measured variable from before to
after an intervention. For example, it could be the change in
ejection fraction after biventricular pacemaker insertion. Avoiding
bias is challenging, because clinical staff know patient character-
istics, whether the patient has had an intervention, and what the
previous measurements have been. Response is an unreliable and
often deceptive metric because, without a control group, it cannot
distinguish among background variation, the natural history of
disease, and the effects of an intervention.
EFFECT
The “effect” is the difference in response between patients that have
undergone an intervention compared with the response of a control
group and thus requires 4 measurements to be compared. This is
more complex but is the key metric that should dominate clinical
decisions about therapeutic interventions because it distinguishes the
effect of an intervention from the natural history of disease. “Efﬁcacy,”
“effectiveness,” “advantage,” “net beneﬁt,” or “net harm” are other
terms that can be used instead of “effect.”
OUTCOME , RESPONSE , AND EFFECT
ARE NOT INTERCHANGEABLE
If 3 patient groups are undergoing an identical intervention, it is
possible that the group that has the best outcome, the group that has
the best response, and the group that receives the greatest effect are
all different (Fig. 1).
Consider a hypothetical example of Agent X, which is known to
dramatically increase left ventricular ejection fraction (LVEF), but
only in patients with dilated cardiomyopathy and low LVEF.
Imagine it being examined in 3 groups:
 Group 1: testing in healthy subjects to establish safety; Group 2: a ﬁrst-in-man open-label study at the center that
invented Agent X, in the early minutes after successful
primary angioplasty for myocardial infarction; and
 Group 3: a double-blind placebo-controlled trial in pa-
tients with dilated cardiomyopathy and low LVEF.
Group 1 will have the best “outcome,” because these subjects have
the highest baseline LVEF. Agent X does not change a normal
LVEF. There is no response and no effect. Group 2 may have the
best “response” because with prompt revascularization myocardial
function will recover substantially in many patients, independent of
Agent X. Group 3 may have the greatest increase in LVEF
attributable to the intervention so it will have received the greatest
“effect.”
If our community judged clinical usefulness on outcome or
response, Agent X might be considered inappropriate for Group 3,
even though they are the only ones who truly beneﬁtted at all.
To illustrate this concept, look at studies of cardiac resynchro-
nization therapy (CRT) by searching for “echocardiography and
CRT” in Europe PubMed Central. Frequently, trials use the terms
“outcome,” “response,” and “effect” (or “beneﬁt”) without a clear
separation in meaning (Fig. 2) and in some cases interchangeably.
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106One pitfall of reporting response is the phenomenon of “regres-
sion to the mean.” If enrollment requires a measurement below a
certain threshold, using a test with an element of variability, such as
LVEF, a measurement taken on 1 particular day might be lower
than the patients’ true average value. When the test is repeated (after
the intervention), the measurement is likely to have risen closer to
the patients’ true average. This may give the false impression of a
therapeutic improvement. Unless there is a control group for com-
parison, a reader may be misled into thinking that an intervention is
effective. Describing an intervention as “effective” should be reserved
for the ﬁndings of randomized controlled trials where there is a
signiﬁcant difference between the intervention and control groups.
The terms “outcome,” “response,” and “effect” are sometimes used
interchangeably in imaging research. We suggest simple deﬁnitions
to facilitate clear communication and avoid misinterpretation of
ﬁndings and even of study design.
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Qualitative Characterization of
Adipose Tissue by MDCT
We read with great interest the paper by Rosenquist et al. (1)
published recently in iJACC. The analysis performed on a large
cohort drawn from the Framingham Heart Study implies that lower
multidetector computed tomography (MDCT) attenuation of sub-
cutaneous adipose tissue and visceral adipose tissue is associated
with an adverse cardiometabolic risk proﬁle. We would like to reﬂect
on 2 aspects of the published data.
First, although imaging of adipose tissue by MDCT offers
relatively high resolution and reproducibility and has increasingly
been used as a research tool, the methodology of computed to-
mography fat volume calculations has never been validated. Mea-
surements are based on an arbitrary attenuation range (Hounsﬁeld
units), which is not set uniformly across the literature. Such
attenuation-based identiﬁcation may lead to the parts of adipose
tissue with the lowest and highest attenuation being left unac-
counted for. Furthermore, attenuation relies substantially on
computed tomography scan parameters, especially tube voltage (kV),
and also on patients’ characteristics. Tube voltage is often set
differently for lean and obese patients. All of these factors may lead
to a systematic bias in interpretation of a study such as that by
Rosenquist et al. (1). Scan parameters applied in the reported cohort
were not mentioned in the paper.Second, we know from basic research studies that adipose tissue may
display either an unfavorable or a favorable metabolic proﬁle (endocrine
and paracrine) depending on its location and metabolic status (2). As
an example, epicardial adipose tissue in patients with coronary artery
disease as opposed to patients without this disease showed intense
leukocyte inﬁltration, thickened interlobular septa, and increased neo-
vascularization (3). All of these elements are more radiodense than
lipid-laden adipocytes and thus may lead to higher, rather than lower,
MDCT attenuation of adipose tissue with a proinﬂammatory and
proatherosclerotic metabolic proﬁle. Results of our clinical study
corroborate this hypothesis (4). Furthermore, as noted by Rosenquist et
al. (1), lower attenuation of subcutaneous adipose tissue and visceral
adipose tissue was correlated with fat volume because larger, lipid-laden
adipocytes are less attenuating. In such circumstances, in a retrospec-
tive, cross-sectional study, it may be difﬁcult to distinguish the effects of
fat volume from those of its attenuation. Thus, it would be interesting
to see how the attenuation correlated with cardiometabolic risk factors
within subgroups with similar fat volumes.
To summarize, the study by Rosenquist et al. (1) adds signiﬁ-
cantly to the growing body of evidence on the research and clinical
role of MDCT-derived characterization of adipose tissue. However,
further research efforts to eliminate the aforementioned limitations
are warranted. Longitudinal designs, histopathology references,
methodological improvements, standardization of MDCT fat
measurements, and prospective methods of accounting for the
established confounding factors in adipose tissue attenuation and
volume measurements should be clariﬁed to further develop this
new, fascinating area of research.
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Myocardial Extracellular Volume
Measurement by Cardiac Magnetic
Resonance
Measuring myocardial extracellular volume (ECV) with cardiovascular
magnetic resonance is achieving increasing importance because it allows
quantiﬁcation of diffuse ﬁbrosis not detectable with conventional late
gadolinium enhancement techniques. However, the conditio sine qua
